BIOY Fees and Costs — GraniteShares YieldBOOST Biotech ETF
Data updated: 2026-09-11
The net expense ratio is 1.07%: a 0.99% management fee plus 0.08% other expenses. There are no sales loads or redemption fees. In fiscal 2026 the fund paid $1K in broker commissions, 0.2094% of average net assets.
BIOY Fees and Expenses
Annual operating expenses and sales charges of BIOY. Prospectus, as of October 24, 2025.
| Annual operating expenses | |
|---|---|
| Management fee | 0.99% |
| 12b-1 fee | 0.00% |
| Other expenses | 0.08% |
| Gross expense ratio | 1.07% |
| Fee waiver | — |
| Net expense ratio | 1.07% |
| Sales charges | |
|---|---|
| Max front load | — |
| Max deferred load | — |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | Yes |
| Fees waived or reduced during the year | Yes |
| Waived fees subject to recoupment | Yes |
BIOY Costs Over Time
On $10,000 invested in BIOY, assuming 5% a year before costs, total costs come to $796 over 5 years, cutting the return by 1.34% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Fund expenses (net expense ratio 1.07%) | $112 | $350 | $604 |
| Trading costs (broker commissions) | $22 | $68 | $118 |
| Lost growth on money paid in costs | $0 | $21 | $73 |
| Total costs | $134 | $439 | $796 |
| Value after costs | $10,366 | $11,138 | $11,967 |
| Impact on return, per year | 1.34% | 1.34% | 1.34% |
BIOY Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending June 30, 2026.
- Explicit cost rate (commissions ÷ average net assets): 0.2094%
- Total broker commissions: $1K
- Bought from dealers (principal trades, not a cost): $393K
- Portfolio turnover (prospectus): —
- Securities lending: none during the year
BIOY Agency Brokers
Commissions paid.
| Broker | Amount | Share |
|---|---|---|
| Stonex Securities Inc. | $1K | 100.00% |
BIOY Dealer Counterparties
Securities bought directly from dealers (principal trades).
| Broker | Amount | Share |
|---|---|---|
| BNY MELLON CAPITAL MARKETS, LLC | $393K | 100.00% |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.